Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E414445-5mg | 5mg | In stock | $92.90 | |
E414445-10mg | 10mg | In stock | $151.90 | |
E414445-25mg | 25mg | In stock | $342.90 | |
E414445-50mg | 50mg | In stock | $434.90 | |
E414445-100mg | 100mg | In stock | $815.90 |
HIF Inhibitors
Synonyms | C17H16N4O4 | CS-0031647 | Glycine, N-((7-hydroxy-5-(2-phenylethyl)(1,2,4)triazolo(1,5-a)pyridin-8-yl)carbonyl)- | JSK7TUA223 | UNII-JSK7TUA223 | Enarodustat (JTZ-951) | JTZ 951 | HY-109057 | BJ162590 | DB14985 | EX-A4798 | MS-25187 | 2-(7-Hydroxy-5-phenet |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Egl nine homolog 1 inhibitor |
Product Description | Information Enarodustat (JTZ-951) Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia. Targets PHD2 (Cell-free assay); EPO release from Hep3B cells (Cell-based assay) 0.22 μM; 5.7 μM(EC50) In vitro Enarodustat (JTZ-951) inhibits PHD2 with IC50 of 0.22 μM and the EPO release from Hep3B cells with EC50 of 5.7 μM. In vivo JTZ-951 (compound 14), with a 5-phenethyl substituent on the triazolopyridine group, increases hemoglobin levels with daily oral dosing in rats. JTZ-951 is rapidly absorbed after oral administration and disappears shortly thereafter, which can be advantageous in terms of safety. JTZ-951 is selected as a clinical candidate. Cell Research(from reference) Cell lines:Hep3B cells Incubation Time:24 h |
ALogP | 1.511 |
---|---|
HBD Count | 2 |
Rotatable Bond | 6 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-[[7-oxo-5-(2-phenylethyl)-3H-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino]acetic acid |
---|---|
INCHI | InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24) |
InChi Key | FJYRBJKWDXVHHO-UHFFFAOYSA-N |
Canonical SMILES | C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O |
Isomeric SMILES | C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O |
PubChem CID | 50899324 |
Molecular Weight | 340.33 |
PubChem CID | 50899324 |
---|---|
ChEMBL Ligand | CHEMBL4297619 |
DrugBank Ligand | DB14985 |
CAS Registry No. | 1262132-81-9 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F2307406 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307407 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307408 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307409 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307410 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307411 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307412 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307413 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307415 | Certificate of Analysis | May 09, 2023 | E414445 |
F2307416 | Certificate of Analysis | May 09, 2023 | E414445 |
Solubility | Solubility (25°C) In vitro DMSO: 68 mg/mL (199.8 mM); Ethanol: 2.5 mg/mL (7.34 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 68 |
DMSO(mM) Max Solubility | 199.806070578556 |
Water(mg / mL) Max Solubility | <1 |
Starting at $241.90
1. Sanford M, McCormack PL. (2017) Erratum Regarding "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD" (Am J Kidney Dis. 2017;69[6]:815-826).. Am J Kidney Dis, 69 (6): (869). [PMID:28532635] [10.1021/op500134e] |
2. Markham A. (2021) Enarodustat: First Approval.. Drugs, 81 (1): (169-174). [PMID:33320297] [10.1021/op500134e] |
3. Ogoshi Y, Matsui T, Mitani I, Yokota M, Terashita M, Motoda D, Ueyama K, Hotta T, Ito T, Hase Y et al.. (2017) Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.. ACS Med Chem Lett, 8 (12): (1320-1325). [PMID:29259755] [10.1021/op500134e] |
4. Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M. (2019) JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.. Eur J Pharmacol, 859 (13): (172532). [PMID:31301309] [10.1021/op500134e] |